- Home
- CCBG vs ABUS Comparison
CCBG vs ABUS Comparison
Compare CCBG & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCBG
- ABUS
- Stock Information
- Founded
- CCBG 1895
- ABUS 2005
- Country
- CCBG United States
- ABUS United States
- Employees
- CCBG N/A
- ABUS N/A
- Industry
- CCBG Major Banks
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- CCBG Finance
- ABUS Health Care
- Exchange
- CCBG Nasdaq
- ABUS Nasdaq
- Market Cap
- CCBG 647.6M
- ABUS 685.7M
- IPO Year
- CCBG N/A
- ABUS N/A
- Fundamental
- Price
- CCBG $41.34
- ABUS $3.22
- Analyst Decision
- CCBG Buy
- ABUS Strong Buy
- Analyst Count
- CCBG 2
- ABUS 4
- Target Price
- CCBG $39.00
- ABUS $5.50
- AVG Volume (30 Days)
- CCBG 38.4K
- ABUS 832.9K
- Earning Date
- CCBG 07-22-2025
- ABUS 07-31-2025
- Dividend Yield
- CCBG 2.32%
- ABUS N/A
- EPS Growth
- CCBG 11.98
- ABUS N/A
- EPS
- CCBG 3.37
- ABUS N/A
- Revenue
- CCBG $236,037,000.00
- ABUS $6,403,000.00
- Revenue This Year
- CCBG $10.45
- ABUS $3.35
- Revenue Next Year
- CCBG $3.50
- ABUS N/A
- P/E Ratio
- CCBG $12.26
- ABUS N/A
- Revenue Growth
- CCBG 6.63
- ABUS N/A
- 52 Week Low
- CCBG $26.72
- ABUS $2.71
- 52 Week High
- CCBG $41.54
- ABUS $4.73
- Technical
- Relative Strength Index (RSI)
- CCBG 71.97
- ABUS 44.33
- Support Level
- CCBG $37.87
- ABUS $3.04
- Resistance Level
- CCBG $41.00
- ABUS $3.65
- Average True Range (ATR)
- CCBG 0.98
- ABUS 0.14
- MACD
- CCBG 0.37
- ABUS -0.03
- Stochastic Oscillator
- CCBG 100.00
- ABUS 32.79
About CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services among others through its banking offices in Florida, Georgia, and Alabama.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.